6 months ago
FDA Approves Cell Based Multiple Myeloma Therapy Discovered In China Recently, Legend Biotech (NASDAQ: LEGN) announced in Somerset, New Jersey, that the U.S. Food and Drug Administration (FDA) has ...
6 months ago
Multiple Myeloma Chinese:High-Risk Multiple Myeloma Patient Achieves Cancer Cell Clearance in the First Month After CAR-T Therapy “Congratulations, you can be discharged. The treatment effica...
6 months ago
Hope Rekindled: The Remarkable Journey of a Pakistani Multiple Myeloma Patient in China Hope of patient “When I first arrived, I couldn’t walk and had a lot of pain in my chest an...
6 months ago
Multiple Myeloma Therapy From China When All Treatment Options Were Exhausted, Cancer Rapidly Progressed, and the Doctor Regretfully Said That Ms. M Did Not Respond to Any Medication. This situatio...
6 months ago
🔬✨ Overall Response Rate 50%! Chinese Research Entity’s Solid Tumor CAR-T Hits Colorectal Cancer Colorectal Cancer #Solidtumor In the journey to conquer cancer, a significant breakthrough i...
6 months ago
Myeloma in chinese: Case Study of Relapsed/Refractory Multiple Myeloma Preface Multiple myeloma (MM) is a malignant disease characterized by clonal proliferation of abnormal plasma cells. In many c...
6 months ago
Myeloma Chinese: Expert Interpretation of Guidelines for Response Assessment and Diagnostic System in Multiple Myeloma Multiple myeloma is a malignant tumor originating from bone marrow stromal cel...
6 months ago
Multiple Myeloma Therapy China Successful “Humanized BCMA CAR-T Cell” Treatment for a Multiple Myeloma Patient with Recurrent Disease at the People’s Hospital of Bozhou City, Anhu...
6 months ago
2024 AACR | China’s Innovative Medicine Leads Globally! Dazzling International with Multi-Cancer Research Achievements AACR2024 #AACR This month, the annual cancer research summit, #AACR,...
6 months ago
FDA Approval CAR-T Multiple Myeloma CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is a form of cellular immunotherapy that involves genetically reprogramming a patient’s own T...
6 months ago
Zevorcabtagene Autoleucel (CT053): China’s Second BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma On March 1, 2024, blood tumor patients welcomed another encouraging...
6 months ago
Equecabtagene Autoleucel (CT103A): A Promising BCMA-Targeted CAR-T Therapy for Multiple Myeloma The development of malignant blood disorders, such as multiple myeloma, is associated with immune def...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
